QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Closes First Tranche of Private Placement; Plans to Release Early Efficacy Data of Lead Candidate in Combination Study
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced that it has closed the first tranche of a non-brokered private placement of up to 20,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of up to approximately C$2,000,000. According to the update, the first tranche comprised of 7,500,000 common shares, each at a price of C$0.10, for gross proceeds of C$750,000. The closing of the second and final tranche of the offering is scheduled to occur in late March 2019. BriaCell intends to use net proceeds…